Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes
Abstract
Thyroid hormones influence heart rate, serum lipids, metabolic rate, body weight and multiple aspects of lipid, carbohydrate, protein and mineral metabolism. Although increased thyroid hormone levels can improve serum lipid profiles and reduce fat, these positive effects are counterbalanced by harmful effects on the heart, muscle and bone. Thus, attempts to use thyroid hormones for cholesterol-lowering and weight loss purposes have so far been limited. However, over the past decade, thyroid hormone analogues that are capable of uncoupling beneficial effects from deleterious effects have been developed. Such drugs could serve as powerful new tools to address two of the largest medical problems in developed countries--atherosclerosis and obesity.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Early attempts to use thyroid hormone to increase thermogenesis and induce weight loss were confounded by tachycardia, bone loss, and muscle catabolism.
“Early attempts to use thyroid hormone (TH) to increase thermogenesis and induce weight loss were confounded by tachycardia, bone loss, and muscle catabolism 144.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [144]
The citation lists haven’t been fetched yet
References 92 · Cited by 253
- Authors
- Baxter, J. D., & Webb, P.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-04
- Volume
- 8
- Issue
- 4
- Pages
- 308-320
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1992711332
- Cited by
- 253
- References
- 92
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 9 · 2023: 8 · 2022: 8 · 2021: 6 · 2020: 9 · 2019: 8 · 2018: 10 · 2017: 23 · 2016: 23 · 2015: 15 · 2014: 28 · 2013: 27 · 2012: 21
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of California, San Francisco
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- thyroid hormone analogs, atherosclerosis, obesity, type 2 diabetes, serum cholesterol, lipid metabolism, weight loss, drug development
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Obesity, Thyroid Hormones, Molecular Mimicry, Anti-Obesity Agents, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
